Dicerna Pharmaceuticals, Inc. (DRNA) relating to its proposed acquisition by Novo Nordisk. Under the terms of the agreement, DRNA shareholders will receive $38.25 in cash per share they own.
Dicerna Pharmaceuticals, Inc. (DRNA) relating to its proposed acquisition by Novo Nordisk. Under the terms of the agreement, DRNA shareholders will receive $38.25 in cash per share they own.